Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Response Evaluation Criteria in Solid Tumors”

61 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 61 results

Post-approval studies (Phase 4)Study completedNCT01493713
What this trial is testing

Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer

Who this might be right for
Colorectal CancerHepatic Metastasis
Grupo Espanol Multidisciplinario del Cancer Digestivo 83
Testing effectiveness (Phase 2)Ended earlyNCT03681951
What this trial is testing

First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors

Who this might be right for
Neoplasms, Pancreatic
GlaxoSmithKline 8
Testing effectiveness (Phase 2)Active Not RecruitingNCT02858921
What this trial is testing

Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

Who this might be right for
Melanoma
Melanoma Institute Australia 60
Large-scale testing (Phase 3)Looking for participantsNCT03592472
What this trial is testing

Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Who this might be right for
Renal Cell Carcinoma
Xynomic Pharmaceuticals, Inc. 413
Not applicableStudy completedNCT04882371
What this trial is testing

Comparison of MRI With PET / CT in the Evaluation of Response to Neoadjuvant Therapy Based on the Molecular Subtypes of Breast Cancer

Who this might be right for
Breast CancerChemotherapy Effect
Cem Ilgin Erol 88
Early research (Phase 1)UnknownNCT05088889
What this trial is testing

Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer

Who this might be right for
Stage IV Pancreatic Cancer
Sheba Medical Center 10
Testing effectiveness (Phase 2)Study completedNCT01284920
What this trial is testing

MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients

Who this might be right for
Prostate CancerProstate NeoplasmsCastration Resistant Prostate Cancer (CRPC)
Astellas Pharma Inc 47
Testing effectiveness (Phase 2)Active Not RecruitingNCT04207086
What this trial is testing

A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma

Who this might be right for
Melanoma Stage III
Melanoma Institute Australia 21
Testing effectiveness (Phase 2)Active Not RecruitingNCT05180695
What this trial is testing

HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas

Who this might be right for
Advanced Soft-tissue SarcomaMetastatic Soft-tissue Sarcoma
Centre Leon Berard 47
Early research (Phase 1)Study completedNCT02944396
What this trial is testing

Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
AbbVie 25
Testing effectiveness (Phase 2)Study completedNCT02699073
What this trial is testing

Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib

Who this might be right for
Metastatic Colorectal Cancer
GERCOR - Multidisciplinary Oncology Cooperative Group 55
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07274384
What this trial is testing

Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)Hyperprogression
Università Vita-Salute San Raffaele 74
Testing effectiveness (Phase 2)Study completedNCT04326257
What this trial is testing

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Who this might be right for
Squamous Cell Carcinoma of the Head and Neck
Dan Zandberg 20
Not applicableStudy completedNCT01116869
What this trial is testing

China CellSearch Study

Who this might be right for
Metastatic Breast CancerBenign Breast Disease
Johnson & Johnson Medical, China 500
Early research (Phase 1)Ended earlyNCT02222363
What this trial is testing

Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors

Who this might be right for
Refractory Cancer
Vivolux AB 19
Testing effectiveness (Phase 2)Study completedNCT01091428
What this trial is testing

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Who this might be right for
Ovarian CarcinomaFallopian Tube CancerPeritoneal Cancer+1 more
Millennium Pharmaceuticals, Inc. 191
Testing effectiveness (Phase 2)Study completedNCT01310036
What this trial is testing

Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 208
Not applicableLooking for participantsNCT07743918
What this trial is testing

Vitamin D Status and Clinical Outcomes in Locally Advanced Cervical Cancer

Who this might be right for
Locally Advanced Cervical CancerVitamin D Concentration
University of Kragujevac 100
Not applicableUnknownNCT03358992
What this trial is testing

Clinical Evaluation for Sarcoma Originated From Bone

Who this might be right for
SensitivitySpecificityHistological Response+1 more
Peking University People's Hospital 300
Not applicableLooking for participantsNCT06527027
What this trial is testing

LN-RADS, RECIST 1.1 and Node-RADS Classification in the Assessment of Lymph Nodes

Who this might be right for
Lymph Node NeoplasmLymph Node Metastasis
Copernicus Memorial Hospital 1,000
Next Page